GeoVax Labs, Inc. (GOVX)
After hours:
| Previous close | 1.2600 |
| Open | 1.1800 |
| Bid | 1.0400 x 1000 |
| Ask | 1.0700 x 1100 |
| Day's range | 1.0400 - 1.1900 |
| 52-week range | 0.5500 - 7.5000 |
| Volume | |
| Avg. volume | 9,882,772 |
| Market cap | 13.426M |
| Beta (5Y monthly) | 1.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9700 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- GlobeNewswire
GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development
Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of John W. Sharkey, PhD to serve as Vice President, Business Development. Dr. Sharkey brings over 30 years of experience in the pharmaceutical and medical device industry, with specific expertise
- GlobeNewswire
GeoVax to Present at BIO International Convention 2022
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the BIO International Convention 2022 being held June 13-16 in San Diego. Details of the presentation are as follows: Date: June 15
- GlobeNewswire
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 shares of common stock at a purchase price of $1.65 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at a p
